

Case Study

# Ditching the Sliding Scale: How Temple Health Cut Hypoglycemia by over 70% with EndoTool SubQ



A system by | **Monarch Medical  
Technologies**

## Background

In 2019, Temple Health's leadership identified a critical need to improve glycemic control - especially among ICU patients. A comprehensive review, led by the nursing director, confirmed that existing insulin dosing protocols were falling short.

After evaluating available solutions, Temple Health chose EndoTool - the only patient-specific insulin dosing system with independently validated, unmatched clinical outcomes.

## Challenge

Prior to adopting EndoTool, Temple Health struggled with inconsistent glycemic control in both ICU and post-operative patients - leading to an elevated risk of complications, including severe hypoglycemia and hyperglycemia.

## The solution

Temple Health first implemented EndoTool IV in late 2019 within their ICUs and ORs, resulting in improved outcomes and clinician satisfaction. Building on this success, the health system expanded its use of EndoTool by introducing the SubQ application at their Jeanes Campus, a smaller community hospital - with plans to scale system-wide.

### Temple Health

"I would emphasize for those contemplating improving their SubQ insulin management that you really have to look at your processes and educate to build confidence with clinicians. Then you'll see the full benefits that EndoTool can deliver."



**David Fleece, MD**  
Chief Medical Information Officer,  
Temple University Hospital

*This case study was adapted from a webinar presented by Dr. David Fleece, Chief Medical Information Officer at Temple Health, titled "Why Every Health System Should Use Patient-Specific Insulin Dosing Software."*




# Key Results

With EndoTool SubQ, Temple Health saw a more than **70% reduction** in glucose readings <70 mg/ dL and an over **85% reduction** in severe hypoglycemia <40 mg/dL compared to the pre-EndoTool baseline.

**Percentage of Patients Using EndoTool:**

Approximately 75% of SubQ patients were managed using the EndoTool algorithm. The remaining 25%, who remained on a traditional sliding scale, also demonstrated some improvement - likely influenced by enhanced nurse education and strengthened operational processes implemented alongside the EndoTool rollout.

Patients managed with a traditional sliding scale showed only modest improvement - falling short of the significant gains achieved with EndoTool SubQ.



TUHS data 2024.

As shared by Dr. David Fleece is the webinar 'Why Every Health System Should Use Patient-Specific Insulin Dosing Software.' [Avaiable here.](#)

## Key outcomes

- 01 There was an over 70% reduction in hypoglycemia for patients using the EndoTool SubQ insulin algorithm.
- 02 Improved glucose management compared to the traditional sliding scale, with marked reductions in both mild and severe hypoglycemia.
- 03 Ongoing system-wide expansion, with plans underway to implement EndoTool SubQ in additional hospitals across the network as part of a broader commitment to patient-specific insulin dosing.

## Insights for Success

At the start, some nursing staff expressed concern about the higher insulin doses recommended by EndoTool, as well as unfamiliarity with basal insulin use.

### Targeted Training & Support

This was addressed through extensive education focused on the safe administration of both short- and long-acting insulins in alignment with the EndoTool algorithm.

### Building Confidence Through Results

With ongoing training and hands-on support from the Monarch team, nursing staff quickly gained confidence. As they observed improved glycemic control and a noticeable reduction in hypoglycemia events, trust in the system grew even stronger.





## Why Leading Health Systems Trust EndoTool

EndoTool is the only patient-specific insulin dosing software, designed to improve glycemic management with real-time adaptability and advanced safety features. EndoTool prevents insulin stacking and hypoglycemia by precisely calculating every dose using multiple clinical factors like kidney function and past insulin administration, offering a level of accuracy unmatched by any other system or protocol. Backed by 50+ independent, peer-reviewed studies, EndoTool is FDA-cleared, fully integrates with major EHRs, and is trusted by top hospitals nationwide. See why leading health systems rely on [EndoTool](#).





Interested in EndoTool  
Patient-Specific Insulin Dosing?

Visit [monarchmedtech.com](https://monarchmedtech.com) today.

Monarch Medical Technologies  
877-349-4582  
[info@monarchmedtech.com](mailto:info@monarchmedtech.com)  
[monarchmedtech.com](https://monarchmedtech.com)

